Latest Period
Q4 2025
Security Snapshot
PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) Institutional Ownership
CUSIP: 729139105
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
95
Shares (Excl. Options)
46,690,012
Price
$1.22
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- PLRX on Nasdaq
- Shares outstanding
- 61,399,727
- Price per share
- $1.36
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 46,690,012
- Total reported value
- $57,540,105
- % of total 13F portfolios
- 0%
- Share change
- -5,637,465
- Value change
- -$7,186,194
- Number of holders
- 95
- Price from insider filings
- $1.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PLRX - PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share is tracked under CUSIP 729139105.
- 95 institutions reported positions in Q4 2025.
- 10 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 95 to 14 between Q4 2025 and Q1 2026.
- Reported value moved from $57,540,105 to $6,061,385.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 95 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 729139105?
CUSIP 729139105 identifies PLRX - PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 729139105:
Significant Owners of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.6% | $9,198,699 | 5,859,044 | TANG CAPITAL MANAGEMENT, LLC | 03 Mar 2025 | |||
| CITADEL ADVISORS LLC | 5% | +2% | $3,711,402 | +$5,414 | 3,042,133 | +0.15% | Kenneth Griffin | 02 Feb 2026 |
| VANGUARD GROUP INC | 4.9% | $3,482,724 | 3,002,348 | The Vanguard Group | 30 Jun 2025 | |||
| Redmile Group, LLC | 4.8% | $4,545,900 | 2,895,478 | Redmile Group, LLC | 31 Dec 2024 | |||
| BlackRock, Inc. | 3.4% | $2,440,674 | 2,104,574 | BlackRock, Inc. | 30 Jun 2025 | |||
| Woodline Partners LP | 3.3% | -57% | $2,471,953 | -$3,023,924 | 2,026,191 | -55% | Woodline Partners LP | 31 Dec 2025 |
| MORGAN STANLEY | 0.9% | -87% | $861,460 | -$5,043,529 | 545,228 | -85% | Morgan Stanley | 31 Dec 2025 |
| FMR LLC | 0.2% | $207,230 | 131,993 | FMR LLC | 28 Feb 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.1% | $137,648 | 87,674 | T. Rowe Price Associates, Inc. | 31 Mar 2025 | |||
| Point72 Asset Management, L.P. | 0.1% | -94% | $56,775 | -$4,926,946 | 46,537 | -99% | Point72 Asset Management, L.P. | 31 Dec 2025 |
As of 31 Dec 2025, 95 institutional investors reported holding 46,690,012 shares of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX). This represents 76% of the company’s total 61,399,727 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 10% | 6,143,132 | +2.3% | 0.37% | $7,494,621 |
| Blue Owl Capital Holdings LP | 4.8% | 2,969,199 | 0% | 1.1% | $3,622,423 |
| VANGUARD GROUP INC | 4.6% | 2,818,241 | +1.5% | 0% | $3,438,255 |
| CITADEL ADVISORS LLC | 4.2% | 2,583,332 | +10% | 0% | $3,151,665 |
| ACADIAN ASSET MANAGEMENT LLC | 3.9% | 2,364,669 | -0.21% | 0% | $2,879,000 |
| Woodline Partners LP | 3.3% | 2,026,191 | -55% | 0.01% | $2,471,953 |
| Monaco Asset Management SAM | 3.2% | 1,938,747 | +136% | 0.7% | $2,365,271 |
| Redmile Group, LLC | 2.6% | 1,616,228 | +1.5% | 0.15% | $1,971,798 |
| Prosight Management, LP | 2.5% | 1,555,744 | +7494% | 0.39% | $1,898,008 |
| BML Capital Management, LLC | 2.5% | 1,546,137 | 0% | 1.7% | $1,886,287 |
| TWO SIGMA ADVISERS, LP | 2% | 1,245,600 | +16% | 0% | $1,519,632 |
| JPMORGAN CHASE & CO | 2% | 1,212,875 | -43% | 0% | $1,479,707 |
| MARSHALL WACE, LLP | 1.8% | 1,080,128 | +261% | 0% | $1,317,756 |
| BlackRock, Inc. | 1.7% | 1,073,272 | -24% | 0% | $1,309,392 |
| UBS Group AG | 1.7% | 1,062,615 | -20% | 0% | $1,296,390 |
| RENAISSANCE TECHNOLOGIES LLC | 1.7% | 1,045,818 | +3.4% | 0% | $1,275,898 |
| Centiva Capital, LP | 1.6% | 1,000,000 | 0.07% | $1,220,000 | |
| TWO SIGMA INVESTMENTS, LP | 1.6% | 953,293 | +22% | 0% | $1,163,017 |
| Peapod Lane Capital LLC | 1.4% | 886,374 | -19% | 0.92% | $1,081,376 |
| Eversept Partners, LP | 1.4% | 842,023 | +2.1% | 0.06% | $1,027,268 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 711,777 | +0.53% | 0% | $868,368 |
| JANE STREET GROUP, LLC | 1.1% | 653,774 | +72% | 0% | $797,605 |
| GSA CAPITAL PARTNERS LLP | 1% | 623,698 | +288% | 0.07% | $761,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.97% | 592,696 | +0.9% | 0% | $723,448 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.91% | 556,938 | +52% | 0% | $679,464 |
Institutional Holders of PLIANT THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (PLRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,838,355 | $6,061,385 | -$191,673 | $1.26 | 14 |
| 2025 Q4 | 46,690,012 | $57,540,105 | -$7,186,194 | $1.22 | 95 |
| 2025 Q3 | 50,406,732 | $74,592,710 | +$1,536,181 | $1.48 | 97 |
| 2025 Q2 | 51,491,424 | $59,725,484 | -$8,565,167 | $1.16 | 112 |
| 2025 Q1 | 57,869,854 | $78,126,006 | -$216,549,992 | $1.35 | 138 |
| 2024 Q4 | 64,754,179 | $852,599,671 | +$21,507,892 | $13.17 | 158 |
| 2024 Q3 | 63,483,171 | $714,277,363 | -$5,607,911 | $11.21 | 149 |
| 2024 Q2 | 63,896,951 | $686,885,070 | -$18,557,994 | $10.75 | 141 |
| 2024 Q1 | 65,187,064 | $971,256,923 | +$41,504,855 | $14.90 | 133 |
| 2023 Q4 | 62,712,668 | $1,135,768,923 | +$100,850,737 | $18.11 | 133 |
| 2023 Q3 | 60,161,028 | $1,043,150,835 | +$29,447,949 | $17.34 | 134 |
| 2023 Q2 | 58,042,121 | $1,051,734,729 | +$9,423,269 | $18.12 | 141 |
| 2023 Q1 | 56,237,135 | $1,495,380,265 | +$312,862,520 | $26.60 | 143 |
| 2022 Q4 | 44,702,851 | $864,087,630 | -$14,811,927 | $19.33 | 123 |
| 2022 Q3 | 45,386,319 | $948,113,021 | +$327,405,105 | $20.89 | 107 |
| 2022 Q2 | 30,133,558 | $241,439,678 | -$11,245,591 | $8.01 | 81 |
| 2022 Q1 | 31,426,255 | $220,339,413 | +$4,111,275 | $7.01 | 85 |
| 2021 Q4 | 30,850,148 | $416,473,043 | +$5,468,177 | $13.50 | 81 |
| 2021 Q3 | 30,380,086 | $512,798,759 | -$14,863,235 | $16.88 | 75 |
| 2021 Q2 | 30,676,131 | $893,270,740 | -$1,364,693 | $29.12 | 80 |
| 2021 Q1 | 30,719,770 | $1,208,139,215 | +$88,069,181 | $39.33 | 76 |
| 2020 Q4 | 28,511,470 | $647,801,804 | +$7,265,154 | $22.72 | 57 |
| 2020 Q3 | 28,195,401 | $635,735,229 | +$17,040,139 | $22.65 | 53 |
| 2020 Q2 | 26,908,341 | $868,442,000 | +$868,442,000 | $32.46 | 36 |